For example, a first-in-human study is in progress to assess the alpha emitter thorium-227 conjugated with a HER2 antibody, with the aim of delivering targeted therapy to HER2-expressing tumors, including breast cancer (ClinicalTrials.gov identifier NCT04147819). Here, ERBB2 is linked to breast carcinoma.